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ABSTRACT 
Introduction: Drug-eluting stents (DES) reduce the risk of restenosis after percutaneous coronary 
intervention. The aim of the study was to evaluate, by intravascular ultrasound (IVUS), the 
minimum lumen area site in the stented segment and the distribution of intimal hyperplasia in 
patients presenting with a DES or bare-metal stent (BMS) in-stent restenosis. 
Methods: The “Nordic Intravascular Ultrasound Study (NIVUS)” study was conducted in Nordic 
and Baltic countries as a prospective multicenter registry. Two hundred and nine patients (DES 
n=121 and BMS n=88) with in-stent restenosis were enrolled.  
Results: At the minimum lumen area site in the stented segment, the stent area (5.8±2.2 mm
2
 vs. 
7.6±2.4 mm
2
, p<0.001) and intimal hyperplasia area (2.6±2.0 mm
2
 vs. 5.0±2.2 mm
2
, p<0.001) were 
significantly lower in patients treated with DES compared to BMS. The percentage of stents that did 
not have a minimum stent area of at least 5.0 mm
2
 (under expansion) was higher in DES (58.7% vs. 
37.7%, p=0.008) compared to BMS. Intimal hyperplasia covered 55.4 ± 33.3% of the stent length in 
the DES compared to 90.7 ± 17.4% in the BMS group, p<0.001. Focal in-stent restenosis was more 
often seen in DES treated patients compared to BMS treated patients (DES n=84 (59.9%) vs. BMS 
n=15 (17.0%), p<0.001). 
 Conclusion: Stent underexpansion was more often seen in DES than BMS in-stent restenosis. DES 
more often had focal in-stent restenosis with less intimal hyperplasia. 
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INTRODUCTION 
  Drug-eluting stents (DES) has reduced the risk of restenosis after percutaneous coronary 
intervention (PCI) compared to bare-metal stents (BMS)
(1-3)
, through reduction of intimal hyperplasia.
(4, 5)
 
Intimal hyperplasia develops over time and in-stent restenosis has been perceived as a benign phenomenon. 
However, both DES and BMS in-stent restenoses may present with unstable angina pectoris, myocardial 
infarction as well as stable angina pectoris.
(6, 7)
 In-stent restenosis remains a clinical problem, as the rate of 
DES in-stent restenosis has been found  to be higher in observational studies and  registries
(8, 9)
 than in  
randomized trials
(2, 10)
, probably due to patient and lesion selection with treatment of less lesion 
complexity
(11)
 and lower risk patients in randomized clinical trials.  
  The cause of restenosis may be biological, mechanical or technical
(12)
 and different 
mechanisms may be responsible for DES and BMS restenosis.
(12-15)
 After balloon dilatation, restenosis has 
mainly been described as a combination of recoil, remodelling, and intima hyperplasia.
(16, 17)
 As recoil is 
reduced by coronary artery stents, BMS restenosis results primarily from intimal hyperplasia.
(13-15)
 In 
contrast, DES failures
(18)
 have been characterized by modest and focal intimal hyperplasia and by 
underexpansion with the stent not achieving a minimum stent area >5.0 mm
2
.
(19, 20)
 Further, other factors such 
as drug resistance and hypersensitivity reactions
(21-23)
 to stent platform, antirestenotic drug and polymer may 
influence the vascular response after coronary DES implantation. 
  The aim of the present prospective multicenter registry was to evaluate, by intravascular 
ultrasound (IVUS), the mechanisms of in-stent restenosis after DES or BMS implantation with focus on the 
minimum lumen area site in the stented segment and the extent and distribution of intimal hyperplasia (IH). 
 
METHODS 
  The “Nordic Intravascular Ultrasound Study – (NIVUS)” study was conducted in 15 
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high-volume percutaneous coronary intervention centers in Nordic and Baltic countries as a 
prospective multicenter registry, where IVUS was used to investigate  patients with in-stent 
restenosis between August 2007 and November 2009. The index stent implantation period ranged 
from June 6, 1996 to December 4, 2009. All patients signed a written informed consent to 
participate in the study. Ethical aspects were considered in accordance with the demands of the 
ethical committees of the participating countries. If the IVUS catheter could not be advanced, or 
there was TIMI 0 flow in the vessel, the protocol allowed dilatation with a 2 mm balloon before 
insertion of the IVUS catheter. 
 
 
IVUS imaging protocol and analysis  
  IVUS was performed after administration of 200 µg intracoronary nitroglycerin. The 
IVUS system was either the Galaxy or I-lab system, (Boston Scientific, Fremont, CA, USA) which 
utilized Atlantis-Pro
TM
 2.6Fr 40 MHz, IVUS catheter or with the Volcano s5 console (Volcano 
Corp., Rancho Cordova, CA, USA) which utilized an Eagle Eye Gold
TM
  2.9 F 20 MHz IVUS 
catheter. Image acquisition using automated transducer pullback at 0.5 mm/s was performed from a 
point at least 10 mm distally to the stent to at least 10 mm proximally to the stent. Off-line analysis 
was performed
(24)
 with a commercially available program for computerized planimetry 
(EchoPlaque, INDEC System, MountainView, CA, USA) at Odense University Hospital. All IVUS 
analyses were performed blinded to stent type and time for the occurrence of the in-stent restenosis. 
Lumen, stent and external elastic membrane (EEM) cross-sectional areas (CSA) were measured 
within the stented segment, and lumen and EEM CSA were measured in the proximal and distal 5 
mm reference segments.  Intimal hyperplasia was calculated as stent minus lumen measures. Peri-
stent plaque CSA was calculated as EEM CSA minus stent CSA in stented segments. ISA was 
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defined as a lack of contact between the stent struts and the underlying vessel wall – not overlying a 
side branch. ISA could not be classified into groups of persistent or acquired, because IVUS was 
not performed post stent implantation stent implantation. Partial stent fracture was defined as >180 
degrees disappearance of stent struts within the stent. Total stent fracture was defined as 360 
degrees disappearance of the stent struts within the stent in a minimum of two continuous frames. 
The patterns of intimal hyperplasia were classified as focal (≤10 mm in length) or diffuse (>10 mm 
in length). If the stent length was shorter than 10 mm and the stent was covered with intimal 
hyperplasia in its entire length it was classified as diffuse IH. 
 
 
In-stent restenosis 
  In-stent restenosis was defined as an angiographic stenosis of more than 50% (visual 
assessed) within the stent. Angiographic follow-up was not scheduled, patients were re-admitted 
due to symptoms, and target lesion revascularization was clinically driven. All in-stent restenoses 
were symptomatic. 
 
 
Statistical analysis 
  The statistical analysis was carried out using SPSS 20.0. Categorical data were 
presented as counts and percentages and compared by the Pearson Chi-Square test or the Fisher 
exact test. For continuous variables with a normal distribution, the mean ± 1SD was reported. For 
variables not normally distributed, the median and interquartile ranges were reported. Continuous 
variables were compared using a Mann-Whitney test or a student’s t-test. Estimates of the 
differences between the groups (and associated 95% confidence interval) for the primary and 
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secondary endpoints of interest are presented. A two-sided P value <0.05 was considered 
statistically significant. 
 Results 
  The study population consisted of 209 patients (DES n=121 (58.1%) and BMS n=88 
(41.9%) who had IVUS performed before treatment for an in-stent restenosis. Median time from 
index PCI to treatment of in-stent restenosis was 411 days [interquartile range (IQR) 183-1117] 
(DES 608 days [IQR 243-1181] vs. BMS median 269 days [IQR 150-977], p=0.005). In 57 (27.3%) 
patients, pre-dilatation with a 2 mm balloon was performed to facilitate the IVUS examination. 
Baseline patient characteristics are presented in Table 1.  
  At the index procedure, there were no differences between the two stent groups 
concerning target vessel characteristics. The index procedure time was longer, and pre and post 
dilation were more often performed in the ES compared to the BMS group (Table 2).  Indication 
for the index procedure was stable angina pectoris (n=127 (61.4%) [DES n=81 (67.5%) and BMS 
n=46 (52.9%]) and acute coronary syndromes (n=80 (38.6%) [DES n=39 (32.5%) and BMS n=41 
(47.1%]), p=0.033. 
 
Clinical presentation at the target lesion revascularization procedure 
  The clinical presentation at the time of the hospitalization for the in-stent restenosis 
was stable angina pectoris (n=152 (72.7%) [DES n=81 (66.9%) and BMS n=71 (81.6%]) and acute 
coronary syndromes (n=56 (27.3%) [DES n=40 (33.1%) and BMS n=16 (18.4%]), p=0.16.  
 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
NIVUS In-stent restenosis 
 
 
7 
 
IVUS measurements 
  At the minimum lumen area site in the stented segment, stent area (DES 5.8 ± 2.2 
mm
2
 vs. BMS 7.6 ± 2.4 mm
2
, p<0.001) and area of intimal hyperplasia (DES 2.6 ± 2.0 mm
2
 vs. 
BMS 5.0 ± 2.2 mm
2
, p<0.001) were smaller in DES (Figure 1 and Table 3), whereas minimum 
lumen CSA was significantly larger in DES compared to BMS (3.1 ± 1.4 mm
2
 vs. 2.6 ± 1.1 mm
2
), 
p=0.003.  
  Overall, the mean MSA was significantly lower in patients treated with DES 
compared to BMS (4.7 ± 1.8 mm
2
 vs. 6.3 ± 2.1 mm
2
, p<0.001) (Table 3). The percentage of stents 
that did not have a MSA of at least 5.0 mm at some location within the stented segment was higher 
in DES (n=71 (58.7%) vs. n=23 (37.7%), p=0.008) compared to BMS treated patients. Assessing 
the minimum lumen area site, the number of stents with MSA <5.0 mm
2
 was lower compared to the 
number at some location within the stented segment, but also at the minimum lumen area site, the 
number of stents with MSA <5.0 mm2 was significantly higher in DES compared to BMS (n=43 
(35.5%) vs. n=8 (9.2%) (Figure 2).  
  Overall, 96.7% of the MSA, measured by IVUS, were smaller than the nominal stent 
area. When stent expansion was defined as the ratio of IVUS measured MSA to nominal stent area, 
the ratio was significantly lower in DES treated patients compared to BMS treated patients (0.60 ± 
0.19 vs. 0.74 ± 0.17, p<0.001). 
   The area of intimal hyperplasia at the MSA site was significantly lower in DES 
compared to BMS (0.7 ± 1.2 mm
2
 vs. 2.7 ± 2.2 mm
2
, p<0.001) and a significantly lower number of 
DES had intimal hyperplasia at the MSA site compared to BMS (DES n=42 (35.0%) vs. BMS n=77 
(87.5%), p<0.001). Also, DES had lower mean area of intimal hyperplasia in the entire stented 
segment and at the maximum stent area site compared to BMS, and in both DES and BMS, the area 
of intimal hyperplasia was larger at the maximum stent area site compared to the MSA site (DES 
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2.3 ± 2.3 mm
2
 vs. 0.7 ± 1.2 mm
2
, p<0.001 and BMS 4.6 ± 2.5 mm
2
 vs. 0.7 ± 1.2 mm
2
, p<0.001, 
respectively). Figure 3 shows an example of DES and BMS with a focal and diffuse in-stent 
restenosis, respectively.  
 Intimal hyperplasia covered 55.4 ± 33.3% of the stent length in the DES compared to 
90.7 ± 17.4% in the BMS group, p<0.001. Focal in-stent restenosis was more often seen in DES 
treated patients compared to BMS treated patients (DES n=84 (59.9%) vs. BMS n=15 (17.0%), 
p<0.001). Among different types of DES, focal in-stent restenosis was more common in Cypher 
n=31 (73.8%) stents than in Taxus n=24 (58.5%) or Endeavor n=7 (36.8%) stents, p=0.022. 
  Stent fractures occurred in 4 (3.3%) DES (partial fracture: Taxus_1 and Endeavor=2, 
total fracture Cypher=2), and 4 (4.5%) in BMS (all total fractures), p=0.23 (Table 3). There was no 
relation between length of the stent and the frequency of stent fractures comparing DES and BMS. 
 
Discussion 
  The present study is a prospective multi-center IVUS assessment of patients with DES 
vs. BMS implantation complicated with in-stent restenosis. Compared to BMS, DES more often had 
focal in-stent restenosis with less intimal hyperplasia at the minimum lumen area site, but more frequent 
stent underexpansion with a minimum stent area < 5.0 mm
2
. Among different types of DES, focal in-stent 
restenosis was more common in Cypher stents than in Taxus or Endeavor stents. 
  Our study confirms that the mechanisms of in-stent restenosis differ between BMS and DES. 
Most BMS had more than 50% intimal hyperplasia area at the minimum lumen area site, whereas stent 
underexpansion with a MSA < 5.0 mm
2
 was found in less than 10% of the BMS in-stent restenosis at the 
minimal lumen area site. This is in line with previous studies
(13-15)
 where in-stent restenosis mainly was the 
result of neointimal tissue proliferation, which tended to be uniformly distributed over the entire length of the 
stent.
(14) 
An angiographic study with BMS and sirolimus-eluting stents with in-stent restenosis found focal 
in-stent restenosis in 47 % of sirolimus-eluting stents with in-stent restenoses and 19% of BMS with in-stent 
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restenoses.
(25)
 In the SIRolImUS (SIRIUS)
(26)
 trial the predictive value of minimum stent area (MSA) for 
long-term patency of sirolimus-eluting stents implantation compared to BMS was assessed and sirolimus-
eluting stents reduced restenosis, resulting in increased predictability of long-term stent patency with post 
procedure MSA. In addition, SES had a considerably lower optimal MSA threshold compared to BMS. 
In the BMS era, most IVUS studies could not rule out a beneficial effect of IVUS guidance, 
although a larger MSA was found in IVUS guided PCI treated patients.
(27-30)
 The “Can Routine Ultrasound 
Influence Stent Expansion (CRUISE) Trial showed that the MSA was a predictor of subsequent target lesion 
revascularization.
(27)
 For BMS the tissue accumulation within the stent has been described to peak at about 6 
months
(31)
 and in-stent restenosis has been reported to occur an average of 5.5 months after stent 
implantation.
(32)
 This is in accordance with the median time from index PCI to the treatment of BMS in-stent 
restenosis of 9 months in our study. In contrast, the median time from index PCI to the treatment of DES in-
stent restenosis was 14 months indicating a slower progression of intimal hyperplasia due to delay of the 
biologic response to vascular injury by the antiproliferative drugs. Likewise, Lee et all showed that the mean 
time from index PCI to detection of in-stent restenosis was approximately 12 months in DES treated 
patients.
(33)
 
  In the present study, we found that at the minimum luminal area site DES more often had 
focal in-stent restenosis and less intimal hyperplasia, but more frequent stent underexpansion with a MSA < 
5.0 mm
2
. Among different types of DES, focal in-stent restenosis was more common in Cypher stents than in 
Taxus or Endeavor stents. Other studies have found that the degree of neointimal growth in zotarolimus-
eluting stents to be similar to that in paclitaxel-eluting stents but less than that in sirolimus-eluting stents
(34)
 
and focal in-stent restenosis to be more common in sirolimus-eluting in-stent restenosis compared to 
paclitaxel-eluting instent restenosis.
(35, 36)
 The number of patients with stent underexpansion and a minimum 
stent area <5.0 mm
2
 was similar to results from Kang et al.
(37)
 who found underexpansion in 42% of DES in-
stent restenoses. However, Kang et al(37) only found the minimum lumen site to be associated with stent 
underexpansion in long lesions with stent length >28 mm.  
  In DES treated patients with in-stent restenosis, we found one third of the stents to have a 
MSA < 5.0 mm
2
 at the minimal lumen area site and overall almost 60% of the DES in-stent restenoses had a 
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MSA < 5.0 mm
2 at some location within the stented segment. DES failures(18) have been characterized as 
only modest, but focal, intima hyperplasia in the setting of DES underexpansion and DES not achieving a 
minimum stent area >5.0 mm
2
, has been reported as a predictor of DES failure.
(19, 20)
 Stent underexpansion 
mostly results from poor expansion during implantation rather than from chronic stent recoil.
(18)
 
From our data it appeared that patients receiving DES were more likely to have diabetes, longer 
lesions, and perhaps more calcified lesions (greater pre-dilatation and post-dilatation) and smaller 
vessels. Serial IVUS acquisitions were not available in the present study, but recently two IVUS 
studies showed chronic stent recoil to be a rare cause of in-stent restenosis.
(38, 39)
 As stent dimensions 
rarely change over time, the MSA of the original stent implantation procedure still has the greatest impact on 
subsequent interventions to treat DES restenosis. 
 
Limitation 
 Our study is associated with the inherent limitations of a registry. However, the 
prospective registration of predefined data and the pro protocol defined end points are likely to 
reduce the bias of a non-randomized analysis. There may be an important inclusion bias, as it was 
left to the operator discretion to perform IVUS of in-stent restenosis lesions. The effect of exclusion 
of the group of patients not having IVUS performed may have influenced our results. IVUS at index 
PCI (pre-intervention and final IVUS) was not done/available. As stent length was longer in DES 
treated lesions we cannot rule out that the DES treated lesions could have been more complex 
lesions compared to the BMS treated lesions. The slightly smaller nominal stent diameter in DES 
treated compared to BMS treated lesions (3.2 ± 0.4 mm vs. 3.3 ± 0.4 mm) should not influence on 
the number of stents not having a minimum stent area of at least 5.0 mm2. Finally, The DES used in 
the study were predominantly first generation and the factors leading to DES failure may not be 
generalized to the current generation DES. 
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Conclusion 
  In patients with in-stent restenosis stent under expansion was more often seen in DES 
than BMS restenosis. Compared to BMS, DES more often had focal in-stent restenosis with less IH.
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Figure legends 
 
Figure 1 
Graphic illustration of stent expansion (stent cross sectional area) and area of intimal hyperplasia obstruction 
at the minimum lumen area site in the stented segment. 
  
Figure 2 
Relation between stent CSA at minimum stent area site and stent CSA at minimum lumen area site. Dots are 
on the upper side of the curve indicating that the stent CSA of the minimum lumen area site are larger than 
the stent CSA at the minimum stent area site. 
 
Figure 3 
Example of a diffuse BMS in-stent restenosis (upper) and a focal DES in-stent restenosis with stent 
underexpansion (lower).    
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 Table 1. Baseline patient characteristics  
 Drug-eluting 
stent 
Bare-metal 
stent 
P 
Number of patients 121 88  
Age, (years) 62.0 ± 11.0 60.5 ± 11.1 0.323 
Male 77 (63.6%) 64 (72.7%) 0.17 
Family history  62 (52.5%) 54 (62.1%) 0.17 
Lipid lowering treatment  115 (95.0%) 79 (89.8%) 0.15 
Antihypertensive treatment  87 (71.9%) 57 (64.8%) 0.27 
Smoking  19 (15.7%) 21 (23.9%) 0.14 
Body mass index (kg/m
2
) 27.9 ± 4.0 28.1 ± 5.2 0.77 
Diabetes mellitus  36 (29.8%) 15 (17.0%) 0.10 
 Insulin treatment  24 (19.8%) 11 (12.5%)  
 Oral treatment  12 (9.9%) 4 (4.5%)  
Single vessel disease  48 (39.7%) 38 (43.2%) 0.28 
Drug-eluting stent type     
 Cypher  41 (33.9%)   
 Taxus  43 (35.5%)   
 Endeavor  20 (16.5%)   
 Other  17 (14.0%)   
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Table 2. Stent related parameters during the initial stent implantation 
 Drug-eluting 
stent 
Bare-metal 
stent 
p 
Nominal stent diameter (mm) 3.2 ± 0.4 3.3 ± 0.4 0.006 
Stent length (mm) 25.0 ± 11.7 21.8 ± 9.9 0.036 
Number of stents per lesion  1.4 ± 0.6 1.2 ± 0.4 0.020 
Pre dilatation  99 (81.8%) 62 (70.5%) 0.16 
Post dilatation  49 (40.5%) 20 (22.7%) 0.023 
Vessel with later in-stent restenosis   0.97 
 Left main  4 (3.3%) 1 (1.1%)  
 Left anterior descending artery  62 (51.2%) 47 (53.4%)  
 Circumflexus  17 (14.0%) 9 (10.2%)  
 Right coronary artery  38 (31.4%) 31 (35.2%)  
Largest balloon (mm) 3.3 ± 0.5 3.4 ± 0.5 0.15 
Implantation pressure (atm) 16.7 ± 5.3 15.8 ± 2.6 0.32 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
NIVUS In-stent restenosis 
 
 
23 
 
Table 3. Intravascular ultrasound parameters in patients with in-stent restenosis 
 Drug eluting 
stent 
Bare metal 
stent 
p 
Mean length of analysed stent segment (mm) 24.5 ± 11.9 20.0 ± 9.1 0.001 
Pre dilation before IVUS assessment  40 (33.1%) 17 (19.3%) 0.028 
Stented segment    
Mean stent CSA (mm
2
) 6.7 ± 1.9 7.9 ± 2.3 <0.001 
Mean EEM CSA (mm
2
) 16.5 ± 4.9 17.4 ± 4.4 0.16 
Mean peristent plaque CSA (mm
2
) 11.3 ± 4.0 13.1 ± 3.9 0.001 
Mean lumen CSA (mm
2
) 4.3 ± 1.9 5.2 ± 2.0 0.001 
Mean intima hyperplasia CSA (mm
2
) 1.5 ± 1.4 3.6 ± 1.9 <0.001 
    
At minimum lumen CSA site    
Stent CSA (mm
2
) 5.8 ± 2.2 7.6 ± 2.4 <0.001 
EEM CSA (mm
2
) 15.4 ± 5.5 16.9 ± 4.6 0.047 
Peristent plaque CSA (mm
2
) 12.3 ± 5.2 14.3± 4.4 0.004 
Lumen CSA (mm
2
) 3.1 ± 1.4 2.6 ± 1.1 0.003 
Intima hyperplasia CSA (mm
2
) 2.6 ± 2.0 5.0 ± 2.2 <0.001 
Number of stents with minimum stent area <5.0 mm
2
 at 
minimum lumen CSA site 
43 (35.5%) 8 (9.2%) <0.001 
    
At minimum stent CSA site    
Stent CSA (mm
2
) 4.7 ± 1.8 6.3 ± 2.1 <0.001 
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EEM CSA (mm
2
) 14.9 ± 5.5 16.0 ± 5.0 0.16 
Peristent plaque CSA (mm
2
) 10.8 ± 5.0 12.3 ± 4.7 0.032 
Lumen CSA (mm
2
) 4.1 ± 1.8 3.6 ± 1.8 0.10 
Intima hyperplasia CSA (mm
2
) 0.7 ± 1.2 2.7 ± 2.2 <0.001 
Number of stents with minimum stent area <5.0 mm
2
  59.2% 37.7% 0.006 
    
At maximal stent CSA site    
Maximal stent CSA (mm
2
) 8.5±2.6 9.7±3.0 0.002 
EEM CSA (mm
2
) 18.2 ± 5.6 19.1 ± 5.5 0.28 
Peristent plaque CSA (mm
2
) 12.0 ± 4.7 14.0 ± 5.1 0.006 
Lumen CSA (mm
2
) 6.2 ± 3.1 5.1 ± 2.9 0.011 
Intima hyperplasia CSA (mm
2
) 2.3 ± 2.3 4.6 ± 2.5 <0.001 
    
Intima hyperplasia at proximal stent edge  62 (51.2%) 74 (84.1%) <0.001 
Intima hyperplasia at distal stent edge  57 (47.1%) 68 (77.3%) <0.001 
Proximal reference segment    
Mean EEM CSA (mm
2
) 16.7 ± 5.4 16.1 ± 4.9 0.44 
Mean Lumen CSA (mm
2
) 6.6 ± 2.9 6.5 ± 2.8 0.85 
Mean Plaque CSA (mm
2
) 10.2 ± 4.2 9.5 ± 4.2 0.38 
    
Distal reference segment    
Mean EEM CSA (mm
2
) 11.9 ± 5.3 13.3 ±5.7 0.09 
Mean Lumen CSA (mm
2
) 5.1 ± 2.6 5.4 ± 2.5 0.52 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
NIVUS In-stent restenosis 
 
 
25 
 
Mean Plaque CSA (mm
2
) 6.7 ± 3.7 7.9 ± 5.3 0.05 
    
Stent fracture 4 (3.3%) 4 (4.5%) 0.23 
Total stent fracture, n 2 5  
Partial stent fracture, n 2 0  
 
Intravascular ultrasound (IVUS), elastic external membrane (EEM), cross sectional area (CSA) 
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Figure 1 
 
Bare-metal stent (BMS) Drug-eluting stent (DES)
BMS 6/88 (7%) DES 7/121  (6%) BMS 72/88 (82%) DES 48/121 (40%)
BMS 7/88 (8%) DES 30/121 (25%)BMS 2/88 (2%) DES 36/121 (29%)
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Figure 2 
Bare-metal stent (BMS) Drug-eluting stent (DES)
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Figure 3 
Proximal reference Distal reference
Proximal stent Distal stent
Proximal stent Distal stent
Mid stent Mid stent
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Intravascular ultrasound assessment of minimum lumen 
area and intimal hyperplasia in in-stent restenosis after 
drug-eluting or bare-metal stent implantation 
The Nordic Intravascular Ultrasound Study (NIVUS) 
 
  
Highlights 
 
 Nordic Intravascular Ultrasound Study – (NIVUS) Registry 
 
 In coronary artery lesions with in-stent restenosis, stent under expansion was more often 
seen in drug-eluting stents than bare-metal stents 
 
 In coronary artery lesions with in-stent restenosis, drug-eluting stents more often had focal 
in-stent restenosis with less intimal hyperplasia compared to bare-metal stents 
 
 Minimum stent area < 5.0 mm2 (underexpansion) was a frequent finding and occurred more 
often in drug-eluting stents compared to bare-metal stents 
 
